What is Semax?
Semax is a synthetic analogue of a fragment of adrenocorticotropic hormone (ACTH), specifically derived from the ACTH(4-7) sequence with an added proline-glycine-proline (Pro-Gly-Pro) chain that prolongs its activity. The full structure is MEHFPGP, a heptapeptide designed to cross the blood-brain barrier and exert central nervous system effects.
Developed in the 1980s by the Institute of Molecular Genetics of the Russian Academy of Sciences, Semax received approval in Russia for clinical use in the 1990s and is prescribed there for stroke, TBI recovery, and various neurological conditions.
How Semax Works
Semax exerts its effects through multiple neurochemical pathways:
- BDNF upregulation: Increases brain-derived neurotrophic factor, supporting neuroplasticity and cognitive function
- Serotonin and dopamine modulation: Influences key neurotransmitter systems involved in mood and cognition
- Anti-inflammatory activity: Reduces pro-inflammatory cytokines in neural tissue
- Neuroprotection: Protects neurons from oxidative stress and hypoxic damage
- Melanocortin receptor activity: Acts on MCRs in the brain to produce cognition-enhancing effects
Research Summary
Cognitive and Neuroprotective Effects
Russian clinical and preclinical research shows significant promise for Semax in cognitive enhancement, attention, and neuroprotection. A series of studies found improvements in memory consolidation, attention performance, and stress resilience in both animal models and human subjects.
Stroke and TBI Recovery
Semax is widely used in Russian neurology for acute stroke management and traumatic brain injury recovery, with clinical data supporting improved functional outcomes when administered in the early post-stroke window.
Optic Nerve Applications
Russian clinical use also includes optic neuritis and retinal degeneration, with some controlled trials reporting stabilization or improvement in visual function.
Safety Considerations
- Nasal spray is the most common delivery route; intranasal Semax avoids first-pass metabolism
- Generally well-tolerated; most reported side effects are mild (nasal irritation, transient headache)
- No serious adverse events documented in Russian clinical literature at therapeutic doses
- U.S. regulatory review of safety/efficacy data has not been conducted
Medical Disclaimer: Semax is not approved by the FDA for human use in the United States. This information is for educational purposes only. Do not use peptides without consulting a licensed healthcare provider.
Legal & Regulatory Status
Semax is a licensed pharmaceutical in Russia and several Eastern European countries. In the United States, it has no FDA approval and is not on any compounding bulk substance list. It exists in a gray-market space, available from overseas suppliers and some U.S. research peptide vendors. Its legal status for personal import and use is ambiguous.
Related Reading
- Selank and Semax: Nootropic Peptides from Russian Research — Comparative review of Semax and Selank’s evidence base, mechanisms, and practical differences
- Peptide Pipeline: Clinical Trials to Watch in 2026 — Status of Semax-related neuropeptide research in Western regulatory contexts
- Peptide Safety: What to Know Before Starting — Safety framework for peptides sourced from outside the U.S. regulatory system
Safety Profile Summary
Semax has been used clinically in Russia for over 30 years with a generally favorable safety record in approved indications. U.S. human clinical data is limited. Reported side effects are mild and transient. Long-term safety in healthy individuals is not well-established.
References & Further Reading
- 1. Gusev EI, et al. The Efficacy of Semax in the Treatment of Patients at Different Stages of Ischemic Stroke. Zh Nevrol Psikhiatr Im S S Korsakova. 2018;118(3 Vyp. 2):61-68. [PubMed ↗]
- 2. Eremin KO, et al. Semax, an ACTH(4-10) Analogue with Nootropic Properties, Activates Dopaminergic and Serotoninergic Brain Systems in Rodents. Neurochem Res. 2005;30(12):1493-500. [PubMed ↗]
- 3. Stavchansky VV, et al. The Effect of Semax and Its C-End Peptide PGP on the Morphology and Proliferative Activity of Rat Brain Cells During Experimental Ischemia. J Mol Neurosci. 2011;45(2):177-85. [PubMed ↗]
- 4. Gusev EI, et al. Effectiveness of Semax in Acute Period of Hemispheric Ischemic Stroke. Zh Nevrol Psikhiatr Im S S Korsakova. 1997;97(6):26-34. [PubMed ↗]